XML 55 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration and License Agreements - Additional Information (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2021
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments       $ 10,900.0    
Acquired in-process research and development       105.3 $ 164.5 $ 154.3
Equity securities fair value amount       63.7 38.2  
Revenues       1,133.5 1,045.9 788.1
Royalty | AbbVie            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenues       22.3 19.2 14.3
Collaborative Arrangement | Heptares            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments       2,600.0    
Acquired in-process research and development       100.0    
Collaborative Arrangement | Takeda            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments       1,900.0    
Acquired in-process research and development         120.0  
Collaborative Arrangement | Idorsia            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments       1,700.0    
Acquired in-process research and development         45.0  
Collaborative Arrangement | Xenon            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments       1,700.0    
Acquired in-process research and development           36.2
Upfront payments made           $ 30.0
Equity securities number of shares (in shares) 0.3          
Share price (in USD per share) $ 19.9755         $ 14.196
Milestone equity purchase payment           $ 20.0
Equity securities fair value amount $ 4.6         14.1
Milestone payment 10.0          
Research and development $ 5.4          
Collaborative Arrangement | Voyager            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments       1,300.0    
Acquired in-process research and development   $ 5.0 $ 113.1      
Upfront payments made           $ 115.0
Share price (in USD per share)           $ 11.9625
Milestone equity purchase payment           $ 50.0
Equity securities fair value amount           54.7
Collaborative Arrangement | B I A L            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payments       75.0    
Research and development         20.0 10.0
Collaborative Arrangement | MTPC            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payment receipts       55.0    
Revenues       15.0    
Deferred revenue recognized       5.7 2.6 0.9
Deferred revenue       1.0    
Collaborative Arrangement | AbbVie            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Potential milestone payment receipts       $ 366.0    
Revenues         $ 30.0 $ 20.0
Collaborative Arrangement | Patents | Minimum | MTPC            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Patent term       10 years    
Collaborative Arrangement | Patents | Minimum | AbbVie            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Patent term       10 years    
Collaborative Arrangement | Common Stock | Xenon            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Equity securities number of shares (in shares)           1.4
Collaborative Arrangement | Common Stock | Voyager            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Equity securities number of shares (in shares)           4.2